Combined inhaled corticosteroid and long-acting ?2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study.

ABSTRACT:

Background and objective

There is presently no clear evidence on the effect of combined treatment for non-cystic fibrosis (non-CF) bronchiectasis with inhaled corticosteroid (ICS) and long-acting ?2-adrenergic agonist (LABA). The objective of this study is to assess the efficacy and safety of salmeterol-fluticasone combined inhaled therapy for non-CF bronchiectasis with airflow limitation.

Methods

An observational study was performed in 120 non-CF bronchiectasis patients diagnosed by high-resolution computed tomography (HRCT) scanning of the chest. Patients received either routine therapy or salmeterol-fluticasone (100/500??g daily) combined inhaled therapy on the basis of routine therapy. Clinical symptoms, health-related quality of life (HRQL), lung function, short-acting ?2-adrenergic agonist (SABA) use, and safety were monitored throughout the study.

Results

OF the 120 subjects, 60 received combined inhaled therapy and 60 received routine therapy. Compared to the control group, the combined inhaled therapy group showed significant improvement in their clinical symptom scores (-2.21 vs. -0.31, P?=?0.002) and a reduction in number of weekly SABA usage (-4.2 vs. 0.1, P?ConclusionOur results show that salmeterol-fluticasone combined inhaled therapy should be effective and safe for non-CF bronchiectasis patients especially for those patients with poor lung function or pseudomonas aeruginosa isolated.

SUBMITTER: Wei P 

PROVIDER: S-EPMC5079324 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature